Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
06:00pm, Thursday, 31'st Jul 2025
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-bas
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
09:00am, Tuesday, 29'th Jul 2025
SAN FRANCISCO , July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesl
3 Bullish Biotech Stocks With Explosive Growth Trends
11:03am, Monday, 21'st Jul 2025
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo
Why Nektar Therapeutics Stock Dived by 3% Today
07:00pm, Thursday, 03'rd Jul 2025
Nektar Therapeutics (NKTR -2.98%) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out
SAN FRANCISCO , July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
07:17am, Tuesday, 01'st Jul 2025
SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy
Nektar Therapeutics Announces Proposed Public Offering
04:02pm, Monday, 30'th Jun 2025
SAN FRANCISCO , June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
02:21pm, Monday, 30'th Jun 2025
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
08:15am, Saturday, 28'th Jun 2025
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary a
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
08:45am, Friday, 27'th Jun 2025
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Why Nektar Therapeutics Stock Was Red-Hot Today
06:45pm, Wednesday, 25'th Jun 2025
The latest biotech stock to explode in price, Nektar Therapeutics (NKTR 19.10%) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering ex
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
01:42pm, Wednesday, 25'th Jun 2025
Nektar Therapeutics NKTR released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
12:31pm, Wednesday, 25'th Jun 2025
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?
01:20pm, Tuesday, 24'th Jun 2025
Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for trea
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
11:41am, Tuesday, 24'th Jun 2025
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
